Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Pfizer Excludes EU Biosimilar Experience From US Epoetin Application

Jun 05 2017

• By Derrick Gingery

Bridge

Related Content

Biosimilars Missing In Action: FDA, Sponsors Quiet About Pending Applications

Jul 27 2015

Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK

May 24 2017

Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same

May 25 2017

Pending Biosimilars

Feb 13 2017

Celltrion's Biosimilar Clinical Evidence Heavily Weighted By Ex-US Data

Feb 15 2016

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Oct 07 2016

EU Data Helps Sandoz’s U.S. Clinical Program For Filgrastim

Jan 12 2015

Related Companies

Pfizer Inc.

Amgen, Inc.

Hospira, Inc.

AbbVie Inc.

Novartis AG

Celltrion, Inc.

Johnson & Johnson

Biogen, Inc.

Genentech, Inc.

Additional Topics

United States Advisory Committees Biosimilars Drug Review Regulation FDA BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window